Yan Tu

Comparative efficacy and safety of PCSK9 inhibitors for lipoprotein(a) reduction: a systematic review and network meta−analysis

Abstract Introduction Lipoprotein(a) [Lp(a)] is a genetically determined cardiovascular risk factor that is largely unaffected by statins. Although PCSK9 inhibitors can lower Lp(a), comparative evidence among agents is limited. Methods We conducted a systematic review and frequen...